Q2 2026 Evogene Ltd Earnings Call

August 18, 2026

Operator: 26 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded 18 August 2026. Before we begin, I would like to caution that certain statements made during this earning conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Evogene Ltd. may from time to time make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, the PSLRA, and other securities law as amended.

Operator: 2026 Results Conference Call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded 18 August 2026. Before we begin, I would like to caution that certain statements made during this earning conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Evogene Ltd. may from time to time make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, the PSLRA, and other securities law as amended.

Speaker #1: 26 results conference call. All participants are present in listen-only mode. Following management's formal presentations, we will open the question-and-answer session. You may send questions via chat.

Speaker #1: Please type your name and company before your question. As a reminder, this conference is being recorded. August 18, 2026. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events.

Speaker #1: This presentation contains forward-looking statements relating to future events, and Evogene Ltd. may, from time to time, make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements.

Speaker #1: As defined in the U.S. Private Securities Litigation Reform Act of 1995 (the PSLRA) and other securities laws as amended, statements that are not statements of historical fact may be deemed to be forward-looking statements.

Operator: Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, except, anticipate, should, planned, estimated, intend, and potential, or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market size and milestones, pipeline, as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

Speaker #1: Such forward-looking statements may be identified by the use of words such as "believe," "expect," "anticipate," "should," "planned," "estimated," "intended," and "potential," or words of similar meaning.

Speaker #1: We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market size and milestones, pipeline, as well as our capabilities and technology.

Speaker #1: Such statements are based on current expectations, estimates, projections, and assumptions, describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict and are not guaranteed of future performance.

Speaker #1: Results are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

Speaker #1: Therefore, actual future results, performance, or achievements—and trends in the future—may differ materially from what is expected or implied by such forward-looking statements, due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups Hamas and Hezbollah and Iran and other regional terrorist groups supported by Iran, as well as any destabilization in Israel, neighboring territories, or the Middle East region, and those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authorities and the U.S.

Operator: Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expected or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah, and Iran and other regional terrorist groups supported by Iran, and any destabilization in Israel, neighboring territories, or the Middle East region, and those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnished with the Israel Securities Authority and the US Securities and Exchange Commission, including those factors under the heading Risk Factors.

Speaker #1: Securities and Exchange Commissions, including those factors under the heading "Risk Factors." Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions.

Operator: Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evogene or the company, nor shall the information or any part of it or the facts of its distribution form the basis of, or be relied on in connection with any action, contract, commitment, or relating thereto or to the securities of Evogene or the company.

Speaker #1: The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evogene or the company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on, in connection with any action, contract, commitment, or relating thereto, or to the securities of Evogene or the company.

Speaker #1: The trademarks included herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Operator: The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. With us on the line will be Nir Nimrodi, Evogene's Chairman of the Board of Directors, Ofer Haviv, President and CEO of Evogene, and Polina Ravzin, VP Finance of Evogene. Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.

Speaker #1: With us on the line will be Nir Nimrodi, Evogene's Chairman of the Board of Directors; Ofer Haviv, President and CEO of Evogene; and Paulina Ravzin, VP Finance of Evogene.

Speaker #1: Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.

Speaker #2: Thank you for joining Evogene's second quarter 2026 analyst call. Today's call will be somewhat different from our usual format. Joining me is Mr. Nir Nimrodi, Chairman of Evogene's Board of Directors.

Ofer Haviv: Thank you for joining Evogene's Q2 2026 analyst call. Today's call will be somewhat different from our usual format. Joining me is Mr. Nir Nimrodi, Chairman of Evogene's Board of Directors. Nir will begin by presenting the board's response to the recent demand by a group of dissident shareholders seeking to replace the company's board. Following Nir's remarks, I will discuss the company's achievement during the H1 of the year and our near-term expectation. We will conclude with a review by Mrs. Polina Ravzin, Evogene's VP Finance, of our financial results, followed by a Q&A session. Nir, please go ahead.

Speaker #3: Nir, we'll begin by presenting the Board's response to the recent demand by a group of dissident shareholders seeking to replace the Company's Board.

Speaker #2: Following Nir's remarks, I will discuss the company's achievements during the first half of the year and our new terms expectations. We will conclude with a review by Mrs. Paulina Ravzin, Evogene's VP Finance, of our financial results, followed by a Q&A session.

Speaker #2: Nir, please go ahead.

Speaker #3: Thank you, Ofer. Good morning, everyone. As Chairman, my primary responsibility, together with my fellow directors, is to position Evogene for long-term, sustainable value creation.

Nir Nimrodi: Thank you, Ofer. Good morning, everyone. As chairman, my primary responsibility, together with my fellow directors, is to position Evogene for long-term sustainable value creation. We share your frustration with the historical share price, and we acted with urgency and determination to address it. Over the past 18 months, we haven't just talked about change, we've delivered it. We have fundamentally transformed Evogene into a lean, AI-driven leader in computational chemistry for pharmaceuticals and crop protection. We have streamlined operations, reduced costs, and optimized our portfolio. The question today is not whether change is necessary, as change has already been executed. The question is how we accelerate the momentum we have created. Interrupting this transformation precisely as it enters its most promising phase is a risk we cannot afford. Our strategy is already delivering tangible results.

Speaker #3: We share your frustration with the historical share price, and we acted with urgency and determination to address it. Over the past 18 months, we haven't just talked about change; we have delivered it.

Speaker #3: We have fundamentally transformed Evogene into a lean, AI-driven leader in computational chemistry for pharmaceuticals and crop protection. We have streamlined operations, reduced costs, and optimized our portfolio.

Speaker #3: The question today is not whether change is necessary, as change has already been executed. The question is how we accelerate the momentum. We have created interrupting distance formation precisely as it enters its most promising phase, which is a risk we cannot afford.

Speaker #3: Our strategy is already delivering tangible results. We established CAMPASS as our core platform, building a first-in-class generative small molecule foundation model and integrating autonomous AI agents in partnership with Google Cloud.

Nir Nimrodi: We established ChemPass as our core platform, building a first-in-class generated small molecule foundation model and integrating autonomous AI agents in partnership with Google Cloud. We secured six key drug development agreements with leading biotechnology companies and premier academic institutions, validating the commercial value of our AI-driven platform, ChemPass AI. We reduced headcount from 117 to 38, creating a highly focused, agile organization. We lowered cash burn from approximately $20.5 million in 2024 to an expected $8.5 to $9.5 million in 2026, with further reductions anticipated in 2027. We raised approximately $11.1 million in new capital, securing the financial runway to execute our plans. Lastly, we monetized Lavie Bio, selling it to ICL for $15.25 million, licensed Biomica phase I asset to Lishan Biotech, focused Casterra on Brazil SAS market, and advanced AgPlenus' novel fungicides discovery.

Speaker #3: We secured six key drug development agreements with leading biotechnology companies and premier academic institutions, validating the commercial value of our AI-driven platform, COMPASS AI.

Speaker #3: We reduced headcount from 117 to 38, creating a highly focused, agile organization. We lowered cash burn from approximately $20.5 million in 2024 to an expected $8.5 to $9.5 million in 2026, with further reductions anticipated in 2027.

Speaker #3: We raised approximately $11.1 million in new capital, securing the financial runway to execute our plans. Lastly, we monetized Lavie Bio, selling it to ICL for $15.25 million, licensed Biomica's phase one asset to Lishan Biotech, focused Casterra on the Brazil SAF market, and advanced ACT Plant's novel fungicides discovery.

Speaker #3: Another strong indication of the confidence in Evogene's long-term potential comes from Mr. Leon Recanati, a member of Evogene's board of directors and a highly respected investor.

Nir Nimrodi: Another strong indication of the confidence in Evogene's long-term potential comes from Mr. Leon Recanati, a member of Evogene's board of directors and a highly respected investor. Mr. Recanati recently made a significant investment in Evogene, and today he is one of the largest shareholders of the company. This recent investment reflects his strong belief in Evogene's strategy, technology, and long-term value creation potential. His commitment demonstrates the confidence he has in the substantial potential of the company and further aligns his interests with those of all other Evogene shareholders. As you may know, we were presented with a demand by a group of dissident investors who are seeking to replace the entire board. Following this recent demand, we approached them openly and in good faith and engaged in a dialogue with them to understand their vision for Evogene.

Speaker #3: Mr. Recanati recently made a significant investment in Evogene and today is one of the largest shareholders of the company. This recent investment reflects his strong belief in Evogene's strategy, technology, and long-term value creation potential.

Speaker #3: His commitment demonstrates the confidence he has in the substantial potential of the company and further aligns his interests with those of all other Evogene shareholders.

Speaker #3: As you may know, we were presented with a demand by a group of dissident investors who are seeking to replace the entire board. Following this recent demand, we approached them openly and in good faith, and engaged in a dialogue with them to understand their vision for Evogene.

Speaker #3: We even offered to collaborate and add representatives of their choosing to our board. They rejected that proposal. More importantly, today this group has failed to present any comprehensive strategic alternative, commercial roadmap, or credible operating plan.

Nir Nimrodi: We even offered to collaborate and add representatives of their choosing to our board. They rejected that proposal. More importantly, to date, this group has failed to present any comprehensive strategic alternative, commercial roadmap, or credible operating plan. Let me be clear, replacing most of a public technology company board is an extremely consequential decision. It should only be considered when there is a superior, fully articulated roadmap on the table. Changing directors is not a strategy, it is a disruption. A vote for this group is a vote to hand the reins of your investment to individuals with no defined plan. The risks dismantling the very momentum derives our value creation today. While we believe in continuity, we also believe in evolution.

Speaker #3: Let me be clear: replacing most of a public technology company board is an extremely consequential decision. It should only be considered when there is a superior, fully articulated roadmap on the table.

Speaker #3: Changing directors is not a strategy; it's a disruption. A vote for this group is a vote to hand the reins of your investment to individuals with no defined plan.

Speaker #3: The risks of dismantling the very momentum that drives our value creation today are significant. While we believe in continuity, we also believe in evolution. This September, assuming that we prevail in the contested election, we will proactively strengthen our board by adding two highly accomplished industry leaders.

Nir Nimrodi: This September, assuming that we prevail in the contested election, we will proactively strengthen our board by adding two highly accomplished industry leaders, Dr. Yael Margolin, a pharmaceutical innovation and commercialization expert, and Mr. Yoshinori Oikawa, a veteran of international biotechnology. These additions ensure our board has the precise world-class expertise required for our next phase of growth, combining fresh perspectives with critical institutional knowledge. This upcoming vote is not about resisting change. On the contrary, it is about enhancing the future we are actively building. Removing a unified board at this critical juncture would destroy the strategic plan we have been implementing and would be a profound disservice to our shareholders. On a personal note, I want to emphasize that I deeply believe in open dialogue and constructive collaboration. My door is always open to all our shareholders.

Speaker #3: Dr. Yael Margolin, a pharmaceutical innovation and commercialization expert, and Mr. Yoshinori Oyakawa, a veteran of international biotechnology. These additions ensure our board has the precise, world-class expertise required for our next phase of growth, combining fresh perspectives with critical institutional knowledge.

Speaker #3: This upcoming vote is not about resisting change. On the contrary, it's about enhancing the future we are actively building. Removing a unified board at this critical juncture would destroy the strategic plan we have been implementing and would be a profound disservice to our shareholders.

Speaker #3: On a personal note, I want to emphasize that I deeply believe in open dialogue and constructive collaboration. My door is always open to all our shareholders.

Speaker #3: If you have thoughts, feedback, or wish to discuss our path forward directly, I am always ready and happy to listen. Our focus is singular: to ensure Evogene reaches its full potential and delivers the value you deserve. We ask for your continued trust and your support for the current board and its enhanced slate of nominees—including the new board members' nominees, Dr. Margolin and Mr. Oyakawa—in the coming vote.

Nir Nimrodi: If you have thoughts, feedback, or wish to discuss our path forward directly, I am always ready and happy to listen. Our focus is singular, to ensure Evogene reaches its full potential and delivers the value you deserve. We ask for your continued trust and your support for the current board and its enhanced slate of nominees, including the new board members nominees, Dr. Margolin and Mr. Oikawa, in the coming vote. Thank you. Ofer, back to you.

Speaker #3: Thank you. Ofer, back to you.

Speaker #2: Thank you, Nir. I would like to echo Nir's comment. Our sharp strategic focus and streamlined organizational structure are already yielding outstanding operational results. First, turning to our Pharma division, since the beginning of this year, we have signed four new drug development agreements.

Ofer Haviv: Thank you, Nir. I would like to echo Nir's comments. Our sharp strategic focus and streamlined organizational structure are already yielding outstanding operational results. First, turning to our pharma division. Since the beginning of this year, we have signed four new drug development agreements. This brings our total active collaborations to six, as Nir noted earlier. I am highly encouraged to report that for two of these collaborations, we have already successfully completed the initial step, hit ID, of our computational platform, ChemPass AI process. The validation results we achieved exceeded our partners' expectations, and we are now actively promoting the next steps of these joint programs. In addition, we are rapidly advancing our internal drug discovery program, which not only holds significant value but also serves as a powerful ongoing validation of our computational platform.

Speaker #2: This brings our total active collaborations to six, as Nir noted earlier. I am highly encouraged to report that for two of these collaborations, we have already successfully completed the initial step—hit ID—of our computational platform, CAMPASS AI process.

Speaker #2: The validation results we achieved exceeded our partners' expectations, and we are now actively promoting the next steps of these joint programs. In addition, we are rapidly advancing our internal drug discovery program, which not only holds significant value but also serves as a powerful, ongoing validation of our computational platform.

Speaker #2: In this program, we successfully completed step two, hit-to-lead, of the CAMPASS AI process and progressed to step three, lead optimization—the generation of unique, proprietary molecules that will serve as a drug candidate to initiate preclinical trials.

Ofer Haviv: In this program, we successfully completed step 2, hit to lead, of the ChemPass AI process and progressed to step 3, lead optimization, the generation of unique proprietary molecules that will serve as the drug candidates to initiate preclinical trials. It is important to emphasize that all of these collaborations and internal programs target therapeutics areas addressing markets with multi-billion USD commercial potential. Importantly, Evogene retains significant commercial rights in the outputs of these joint activities. We anticipate generating revenues as these molecules advance through the development pipeline. Every new partnership we secure and every development milestone we achieve brings our programs closer to commercialization, increasing the value and expanding Evogene's future revenue potential. In addition, we are seeing similar highly encouraging momentum in our ag division, specifically in our crop protection program. We have made substantial progress in our program to develop a novel fungicide targeting Septoria.

Speaker #2: It is important to emphasize that all of these collaborations and internal programs target therapeutic areas addressing markets with multi-billion-dollar commercial potential. Importantly, Evogene retains significant commercial rights in the outputs of these joint activities.

Speaker #2: We anticipate generating revenues as these molecules advance through the development pipeline. Every new partnership we secure and every development milestone we achieve brings our programs closer to commercialization, increasing the value and expanding Evogene's future revenue potential.

Speaker #2: In addition, we are seeing similarly encouraging momentum in our Ag division, specifically in our crop protection program. We have made substantial progress in our program to develop a novel fungicide targeting septoria.

Speaker #2: We are nearing the completion of step three, lead optimization, of the CAMPASS AI process, and we are currently testing synthesized molecules in advanced biological assays ahead of launching greenhouse and field trials.

Ofer Haviv: We are nearing the completion of step 3, lead optimization of the ChemPass AI process, and we are currently testing synthesized molecules in advanced biological assays ahead of launching greenhouse and field trials. None of this would be possible without the continuous exceptional growth of our core computational platform, which underwent a massive upgrade this year. Following the signing of our second agreement with Google Cloud, we have already reached our first major project milestone. As a result, we have integrated advanced AI agents into our workflow. These agents automate highly complex, time-consuming tasks that previously required highly specialized researchers weeks or months to complete. Today, we execute those tasks in a matter of minutes. We have also added powerful new predictive models that identify winning candidate molecules.

Speaker #2: None of this would be possible without the continuous, exceptional growth of our core computational platform, which underwent a massive upgrade this year. Following the signing of our second agreement with Google Cloud, we have already reached our first major project milestone.

Speaker #2: As a result, we have integrated an advanced AI agent into our workflow. This agent automates highly complex, time-consuming tasks that previously required highly specialized researchers weeks or months to complete.

Speaker #2: Today, we execute those tasks in a matter of minutes. We have also added powerful new predictive models that identify winning candidate molecules. A key example is our recently announced APP, Antifungal Potency Predictor Model, which predicts a molecule's activity within the actual pathogen itself, rather than just its interaction with the target protein.

Ofer Haviv: A key example is our recently announced APP, anti-fungal potency predictor model, which predicts a molecule's activity within the actual pathogen itself rather than just its interaction with the target protein. Furthermore, the size of our virtual chemical space has expanded dramatically from 36 billion molecules to 110 billion molecules that we can now rapidly scan. Looking ahead, we continue to be laser-focused on achieving the following key objectives. Progressing our existing research collaboration programs across both our pharma and agriculture pipelines. Securing new drug development collaborations with other leading biotechnology companies while simultaneously initiating discussions with major pharmaceutical companies for joint activity. Advancing our high-value internal programs in both pharma and crop protection, which present tremendous commercial upside for our shareholders. Establishing strategic partnerships with top-tier global ag chemical companies.

Speaker #2: Furthermore, the size of our virtual chemical space has expanded dramatically from 36 billion molecules to 110 billion molecules that we can now rapidly scan.

Speaker #2: Looking ahead, we continue to be laser-focused on achieving the following key objectives: progressing our existing research collaboration programs across both our pharma and agriculture pipelines, securing new drug development collaborations with other leading biotechnology companies, while simultaneously initiating discussions with major pharmaceutical companies for joint activity, and advancing our high-value internal programs in both pharma and crop protection, which present tremendous commercial upside for our shareholders.

Speaker #2: Establishing strategic partnership with top-tier global ag chemical companies, continuously upgrading our computational technology, advancing towards increasing autonomous computational systems designed to predict key success requirements at the earliest stage of development.

Ofer Haviv: Continuously upgrading our computational technology, advancing towards increasing autonomous computational systems designed to predict key success requirements at the earliest stages of development. To conclude, I want to strongly reinforce Meir's message. The transformation of Evogene is not a distant promise. It is happening right now, and the execution is undeniable. This level of rapid progress and technological breakthrough is only possible because we have a deeply aligned board and management team working with a shared, precise vision. I am absolutely confident that our current board, strengthened by the world-class expertise of our newly nominated directors, provides the stable, strategic, and highly capable leadership needed to maximize the value of our technology and drive this company to the significant commercial success we all anticipate. Now is the time for execution and continuity, not disruption.

Speaker #2: To conclude, I want to strongly reinforce Nir's message. The transformation of Evogene is not a distant promise—it is happening right now, and the execution is undeniable.

Speaker #2: This level of rapid progress and technological breakthrough is only possible because we have a deeply aligned board and management team working with a shared, precise vision.

Speaker #1: I'm absolutely confident that our current board, strengthened by the world-class expertise of our newly nominated directors, provides the stable, strategic, and highly capable leadership needed to maximize the value of our technology and drive this company to the significant commercial success we all anticipate.

Speaker #1: Now is the time for execution and continuity, not disruption.

Ofer Haviv: Now is the time for execution and continuity, not disruption. We strongly ask for your vote to support the current board and its nominees so we can keep this powerful momentum moving forward. With that, I will hand the discussion over to Polina to review our financial results.

Speaker #2: We strongly ask for your vote to support the current board and its nominees so we can keep this powerful momentum moving forward. With that, I will hand the discussion over to Paulina to review our financial results.

Ofer Haviv: We strongly ask for your vote to support the current board and its nominees so we can keep this powerful momentum moving forward. With that, I will hand the discussion over to Polina to review our financial results.

Speaker #3: Thank you, Ofer. I would like to reinforce the points Nir made regarding the significant transformation Evogene has undergone, particularly the refocusing of our activities and the decisive steps we have taken to implement our new strategy.

Polina Ravzin: Thank you, Ofer. I would like to reinforce the points Nir made regarding the significant transformation Evogene has undergone, particularly the refocusing of our activities and decisive steps we have taken to implement our new strategy. As you heard from Ofer and his update on our subsidiaries, we have moved quickly to realign our operations and resources with our strategic priorities. From a financial perspective, this has meant significantly reducing our operating expenses, preserving and maximizing the cash resources available across the group, and focusing our investments on the areas where we believe Evogene can create the greatest long-term value. The Q2 financial results provide an important foundation for the quarters ahead and reflect many of the actions we have already taken to create a more focused, disciplined, and financially sustainable organization. I will start with the status of our non-core subsidiaries.

Speaker #3: As you heard from Ofer and his update on our subsidiaries, we have moved quickly to align our operations and resources with our strategic priorities.

Speaker #3: From a financial perspective, this has meant significantly reducing our operating expenses, preserving and maximizing the cash resources available across the group, and focusing our investments on the areas where we believe Evogene can create the greatest long-term value.

Speaker #3: The second-quarter financial results provide an important foundation for the quarters ahead and reflect many of the actions we have always taken to create a more focused, disciplined, and financially sustainable organization.

Speaker #3: I will start with the status of our known core subsidiaries. Consistent with our revised strategy, we continue to manage the burn down or transition of our non-core business activities in a disciplined manner.

Polina Ravzin: Consistent with our revised strategy, we continue to manage the wind down or transition of our non-core business activities in a disciplined manner. Lavie Bio is no longer operational. Under the ICL transaction, two additional payments remain due to the company. The first payment was received in July 2026, and the second is expected in July 2027. In addition, during the Q1 2026, Lavie Bio received court approval to distribute a $4.25 million dividend to its shareholders, of which Evogene was entitled to approximately $2.9 million. The dividend distribution was completed during the Q2 2026. Biomica, following the successful completion of its phase I clinical trial and the licensing of its lead oncology candidate, BMC128 to Lishan Pharmaceuticals, is no longer conducting ongoing operations.

Speaker #3: Lavie Bio is no longer operational. Under the ICL transaction, two additional payments remain due to the company. The first payment was received in July 2026, and the second is expected in July 2027.

Speaker #3: In addition, during the first quarter of 2026, Lavie Bio received court approval to distribute a $4.25 million dividend to its shareholders, of which Evogene was entitled to approximately $2.9 million.

Speaker #3: The dividend distribution was completed during the second quarter of 2026. Biomica, following the successful completion of its Phase I clinical trial and the licensing of its lead oncology candidate, BMC128, to Lichen Pharmaceuticals, is no longer conducting ongoing operations.

Speaker #3: In April 2026, Biomica received court approval to distribute a $2.7 million dividend to its shareholders, of which Evogene was entitled to approximately $1.35 million.

Polina Ravzin: In April 2026, Biomica received court approval to distribute a $2.7 million dividend to its shareholders, of which Evogene was entitled to approximately $1.35 million. The dividend distribution was completed during Q2 2026. Casterra has significantly reduced and realigned its operations and is now focused exclusively on Brazil. Evogene raised approximately $0.8 million through its ATM program during Q2 2026, and an additional amount of approximately $2.4 million during Q3 2026. Turning now to the financial results, I would like to highlight the key figures for H1 and Q2 2026. As of 30 June 2026, Evogene held consolidated cash and cash equivalents of approximately $9.3 million. Consolidated cash usage during Q2 2026 was approximately $2.1 million.

Speaker #3: The dividend distribution was completed during the second quarter of 2026. Castella has significantly reduced and realigned its operations and is now focused exclusively on Brazil.

Speaker #3: Evogene raised approximately $0.8 million through its ATM program during the second quarter of 2026, and an additional amount of approximately $2.4 million during the third quarter of 2026.

Speaker #3: Turning now to the financial results, I would like to highlight the key figures for the first half and second quarter of 2026. As of June 30th, 2026, Evogene held consolidated cash and cash equivalents of approximately $9.3 million.

Speaker #3: Consolidated cash usage during the second quarter of 2026 was approximately $2.1 million. For the full year 2026, we expect cash usage to be in the range of approximately $8.5 to $9.5 million.

Polina Ravzin: For the full year 2026, we expect cash usage to be in the range of approximately $8.5 to $9.5 million. Managing our cash position remains a key priority, and we are taking disciplined actions to further reduce cash burn while preserving the capabilities needed to execute our strategic priorities and advance our most promising business opportunities. This disciplined approach is already reflected in our results. The Q2 net loss reduced to approximately $1.8 million, compared with approximately $4.7 million in Q2 2025 and approximately $6 million in Q2 2024. Revenues for H1 2026 totaled approximately $0.7 million, compared to approximately $2.9 million in H1 2025, a decrease of approximately $2.2 million. The decrease was primarily attributable to lower revenue from Casterra, as H1 2025 included approximately $2 million in significant Casterra seed sales.

Speaker #3: Managing our cash position remains a key priority, and we are taking disciplined actions to further reduce cash burn while preserving the capabilities needed to execute our strategic priorities and advance our most promising business opportunities.

Speaker #3: This disciplined approach is already reflected in our results. The second-quarter net loss reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025.

Speaker #3: Approximately $6 million in the second quarter of 2024. Revenues for the first half of 2026 totaled approximately $0.7 million, compared to approximately $2.9 million in the first half of 2025, a decrease of approximately $2.2 million.

Speaker #3: The decrease was primarily attributable to lower revenue from Castella, as the first half of 2025 included approximately $2 million in significant castor seed sales.

Speaker #3: Revenues for the second quarter of 2026 were approximately $0.3 million, compared with approximately $0.5 million in the second quarter of 2025. The decrease was primarily attributable to the conclusion of a planned agreement with Bio in May 2026.

Polina Ravzin: Revenues for Q2 2026 were approximately $0.3 million, compared with approximately $0.5 million in Q2 2025. The decrease was primarily attributable to the conclusion of AgPlenus' agreement with Bayer in May 2026. Research and development expenses, net of non-refundable grants for H1 2026 were approximately $2.9 million, compared with approximately $3.5 million in the corresponding period of 2025, a decrease of approximately $0.6 million. The decrease was primarily attributable to lower R&D expenses at Casterra and AgPlenus, partially offset by increased R&D expenses at Evogene, as the company redirected its R&D efforts towards activities that are core to and support the execution of its new strategy. The decrease in R&D expenses was partially offset by the impact of exchange rate fluctuations between the US dollar and the NIS of approximately $0.4 million.

Speaker #3: Research and development expenses, net of non-refundable grants, for the first half of 2026, were approximately $2.9 million, compared with approximately $3.5 million in the corresponding period of 2025.

Speaker #3: A decrease of approximately $0.6 million. The decrease was primarily attributable to lower R&D expenses at Castella and at Planus, partially offset by increased R&D expenses at Evogene, as the company redirected its R&D efforts towards activities that are core to and support the execution of its new strategy.

Speaker #3: The decrease in R&D expenses was partially offset by the impact of exchange rate fluctuations between the US dollar and the NIS of approximately $0.4 million.

Speaker #3: For the second quarter, R&D expenses were approximately $1.4 million, compared with approximately $1.7 million in the second quarter of 2025. This decrease is mainly attributable to decreased expenses in Castella, partially offset by increased expenses in Evogene, as mentioned in both.

Polina Ravzin: For Q2, R&D expenses were approximately $1.4 million, compared with approximately $1.7 million in Q2 2025. This decrease is mainly attributable to decreased expenses in Casterra, partially offset by increased expenses in Evogene, as mentioned above. In addition, the decrease was partially offset by the impact of exchange rate fluctuations between the US dollar and the NIS of approximately $0.2 million. Sales and marketing expenses for H1 2026 were approximately $0.7 million, essentially unchanged from the corresponding period of 2025. For Q2, sales and marketing expenses were approximately $0.3 million, compared with approximately $0.4 million in Q2 2025. General administrative expenses for H1 2026 decreased slightly to approximately $2 million, compared with approximately $2.1 million in the corresponding period of 2025.

Speaker #3: In addition, the decrease was partially offset by the impact of exchange rate fluctuations between the US dollar and the NIS, of approximately $0.2 million.

Speaker #3: Sales and marketing expenses for the first half of 2026 were approximately $0.7 million, essentially unchanged from the corresponding period in 2025. For the second quarter, sales and marketing expenses were approximately $0.3 million, compared with approximately $0.4 million in the second quarter of 2025.

Speaker #3: General administrative expenses for the first half of 2026 decreased slightly to approximately $2 million, compared with approximately $2.1 million in the corresponding period of 2025.

Speaker #3: The decrease in G&A expenses at Evogene and its subsidiaries was substantially offset by approximately $0.2 million of transaction costs related to the warranty inducement transaction and other legal expenses, as well as approximately $0.2 million resulting from exchange rate fluctuations between the US dollar and the NIS.

Polina Ravzin: The decrease in G&A expenses at Evogene and its subsidiaries were substantially offset by approximately $0.2 million of transaction costs related to the warrant issuance transaction and other legal expenses, as well as approximately $0.2 million resulting from exchange rate fluctuations between the US dollar and the shekel. For Q2 2026, G&A expenses were approximately $0.9 million, compared with approximately $1 million in the corresponding period of 2025. For H1 2026, financing expenses net were approximately $1.7 million, compared with financing income net of approximately $0.8 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in August 2024 fundraising and the February 2026 warrant inducement transaction. Importantly, this result includes significant non-cash accounting impacts.

Speaker #3: For the second quarter of 2026, G&A expenses were approximately $0.9 million, compared with approximately $1 million in the corresponding period of 2025.

Speaker #3: For the first half of 2026, financing expenses, net, were approximately $1.7 million, compared with financing income, net, of approximately $0.8 million in the corresponding period of 2025.

Speaker #3: This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 fundraising and the February 2026 warrant inducement transaction.

Speaker #3: Importantly, these results include significant non-cash accounting impacts. In connection with the February 2026 warrant inducement transaction, the company recorded financial expenses of approximately $3.8 million during the first half of 2026.

Polina Ravzin: In connection with the February 2026 warrant inducement transaction, the company recorded financial expenses of approximately $3.8 million during H1 2026, while also recording approximately $2.1 million of financing income related to the revaluation of the warrant liability as of 30 June 2026. For Q2 2026, we recorded financing income net of approximately $1 million, compared with financing expenses net of approximately $0.3 million in Q2 2025. The improvement was primarily related to the warrant accounting and revaluation of the warrant liability, as described above. Loss from discontinued operations net for H1 2026 was approximately $0.5 million, compared to approximately $3.6 million in the corresponding period of 2025. For Q2 2026, loss from discontinued operations was approximately $0.2 million, compared with approximately $1.7 million in Q2 2025.

Speaker #3: While also recording approximately $2.1 million of financing income related to the revaluation of the warrant liability as of June 30, 2026. For the second quarter of 2026, we recorded net financing income of approximately $1 million, compared with net financing expenses of approximately $0.3 million in the second quarter of 2025.

Speaker #3: The improvement was primarily related to the warrant accounting and revaluation of the warrant liability as described above. Loss from discontinued operations, net, for the first half of 2026 was approximately $0.5 million, compared to approximately $3.6 million in the corresponding period of 2025.

Speaker #3: For the second quarter of 2026, loss from discontinued operations was approximately $0.2 million, compared with approximately $1.7 million in the second quarter of 2025.

Speaker #3: This amount primarily reflects the financial results of V Bio and Biomica, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single line of profit and loss.

Polina Ravzin: These amounts primarily reflect the financial results of Lavie Bio and Biomica, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single line item in our consolidated statements of profit and loss. Following the sale of a majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag to ICL in July 2025 and the licensing of BMC128 to Lishan Pharmaceuticals in February 2026, the operating expense level associated with Lavie Bio and Biomica have decreased significantly. Finally, our net loss for H1 2026 was approximately $7.7 million, essentially unchanged from the corresponding period of 2025. However, the Q2 results show significant improvement. Net loss for Q2 2026 was approximately $1.8 million, compared to approximately $4.7 million in Q2 2025, an improvement of approximately $2.9 million or nearly 62%.

Speaker #3: Following the sale of a majority of V Bio's assets, as well as Evogene's MicroBoost AI for Ag to ICL in July 2025, and the licensing of BMC-128 to Lichen Pharmaceuticals in February 2026, the operating expense levels associated with V Bio and Biomica have decreased significantly.

Speaker #3: Finally, our net loss for the first half of 2026 was approximately $7.7 million, essentially unchanged from the corresponding period of 2025. However, the second quarter results show significant improvement.

Speaker #3: Net loss for the second quarter of 2026 was approximately $1.8 million, compared to approximately $4.7 million in the second quarter of 2025, an improvement of approximately $2.9 million, or nearly 62 percent.

Speaker #3: This improvement was primarily driven by lower operating expenses, a significantly lower loss from discontinued operations, and higher financing income, net. And with that, I have concluded my review of the second quarter financial results, and I will now hand the call back to Ofer.

Polina Ravzin: This improvement was primarily driven by lower operating expenses, a significantly lower loss from discontinued operations, and higher financing income net. With that, I have concluded my review of the Q2 financial results and will now hand the call back to Ofer.

Speaker #1: Thank you, Paulina. Let me close by emphasizing one important point. The transformation near described is not simply a strategic vision; it is already reflected in the way we operate and in our financial performance.

Ofer Haviv: Thank you, Polina. Let me close by emphasizing one important point. The transformation Nir described is not simply a strategic vision. It is already reflected in the way we operate and in our financial performance. We have taken decisive steps to streamline the company, substantially reduce activities in non-core business, lower our operating expenses, and deploy our capital with greater discipline. At the same time, we have protected the technological capabilities and strategic flexibility that we believe are essential to advancing Evogene's most promising operations and creating long-term value. The actions we have taken during 2025 and the H1 2026 have created a stronger and more disciplined financial foundation for the company. We are entering the H2 of the year with a clear focus, a leaner organization, and a much more capital-efficient operating model.

Speaker #1: We have taken decisive steps to streamline the company, substantially reduce activities in on-call business, lower our operating expenses, and deploy our capital with greater discipline.

Speaker #1: At the same time, we have protected the technological capabilities and strategic flexibility that we believe are essential to advancing Evogene's most promising operations and creating long-term value.

Speaker #1: The action we have taken during 2025 and the first half of 2026 has created a stronger and more disciplined financial foundation for the company.

Speaker #1: We are entering the second half of the year with a clear focus on leaner organizations and a much more capital-efficient operating model. Most importantly, we believe this puts Evogene in a stronger position to execute with greater focus, greater discipline, and greater ability to convert our technology and innovation into meaningful commercial opportunities.

Ofer Haviv: Most importantly, we believe this puts Evogene in a stronger position to execute with greater focus, greater discipline, and greater ability to convert our technology and innovation into meaningful commercial opportunities. With that, I would like to thank you for joining us today. We are now happy to open the call for your questions.

Speaker #1: With that, I would like to thank you for joining us today. We are now happy to open the call for your questions.

Speaker #2: Thank you. Ladies and gentlemen, at this time we'll begin the question-and-answer session. To send a question, please use the chat button located at the bottom of your screen.

Operator: Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. In order to send a question, use the chat button located at the bottom of your screen. Please type your full name and your company's name before the question. The first question: When was the last time you used the ATM? I noticed that the number of outstanding shares increased by approximately 2.5 million.

Speaker #2: Please type your full name and your company's name before the question.

Speaker #4: The first question: When was the last time you used the ATM? I noticed that the number of outstanding shares increased by approximately 2.5 million.

Speaker #5: Hi, this is Ofer answering this question. So, we are using the ATM constantly, and according to the market conditions, we decide whether to use it or not.

Ofer Haviv: Hi, this is Ofer answering this question. We are using the ATM constantly, and according to the market condition, we decide when to use it or not. This is part of our strategy to raise money, and we found it is probably the most efficient and less expensive way to raise money. We usually report on how we utilize the ATM every six months in our regular reporting system. I am sure that all of the information, as usual, will be available in this report.

Speaker #5: This is part of our strategy to raise money. We found it is probably the most efficient and least expensive way to raise funds. And we usually report on how we utilize the ATM in our regular reporting system every six months.

Speaker #5: And I'm sure that all of the information, as usual, will be available in this report.

Speaker #4: The next question: Can you monetize your IP technologies with a major strategic partner in the near term? Whether that would be a technology partner, Google, etc., one of our subsidiaries, or the Champus engine?

Operator: The next question: Can you monetize your IP technologies with a major strategic partner in the near term, whether that would be a technology partner, Google, et cetera, one of our subsidiaries or the ChemPass engine?

Speaker #5: So, when we are evaluating our technology, and we did so, we look at all the companies that are focusing on small molecule discovery for pharma and for the AD.

Ofer Haviv: When we are evaluating our technology, and we did so, we look at all the companies that are focusing on small molecule discovery for pharma and for the ag. In the ag, there are not many at all. I think that Evogene is one of the major companies in the field. In pharma, there are additional companies in the same area of activity, and then you can divide them into huge companies, which usually are working on their own pipelines and less in favor of other companies. There is a small company that is competing with what Evogene is doing. I think that the fact that Evogene is entering into this field after many, many years of experience and how to use computational technology to address chemical and biology challenges, I think, puts us in a very strong position.

Speaker #5: In the app, there are not many at all. I think that Evogene is one of the major companies in this field. In pharma, there are additional companies in the same area of activity.

Speaker #5: And then you can divide them to huge companies, which usually are working on their own pipeline and less in favor of other companies.

Speaker #5: There is a small company that is competing with what Evogene is doing. I think that the fact that Evogene is actually entering into this field after many, many years of experience in how to use contextual technology to address chemical and biological challenges puts us in a very strong position.

Speaker #5: And the fact is that even though we have opened our activity in this area less than a year ago, we already have a big collaboration agreement, and we are now talking with additional companies on additional collaborations.

Ofer Haviv: The fact is that even though we are open our activity in this area less than a year, we already have six collaboration agreements, and we are now talking with additional companies on additional collaboration. What I am very excited to see is that we are now starting to talk also with pharma companies, and we start to see initial interest in our technology and what we can offer them. The last is that today, when we are talking on additional collaboration agreement, in the majority of our ongoing discussion, we are also talking about R&D fee to fund our activity. This is something that we have not done at the beginning of our activity in this field. I believe that it will also be reflected in our future revenue item, which makes me very excited and the feeling that we are really offering something unique.

Speaker #5: What I'm very excited to see is that we are now starting to talk with pharma companies, and we are beginning to see initial interest in our technology and what we can offer them.

Speaker #5: And the last is that today, when we are talking about an additional collaboration agreement, in the majority of our ongoing discussions, we are also talking about R&D fees to fund our activity, which is something that we haven't done at the beginning of our activity in this field.

Speaker #5: And I believe that it will also be reflected in our future revenue items, which makes me very excited and feel that we are really offering something unique.

Ofer Haviv: I believe that it will also be reflected in our future revenue item, which makes me very excited and the feeling that we are really offering something unique. Usually, I do not think that it is common to make comparisons of other companies, but I feel that we are in a very, very good place in the field of small molecule discovery, targeting a specific protein.

Speaker #5: And usually, I don't think that it's common to make comparisons to other companies, but I feel that we are in a very, very good place in the field of small molecule discovery targeting a specific protein.

Ofer Haviv: Usually, I do not think that it is common to make comparisons of other companies, but I feel that we are in a very, very good place in the field of small molecule discovery, targeting a specific protein.

Speaker #4: The next question: How long do you expect the field trial to take for the Septoria agricultural program?

Operator: The next question: How long do you expect the field trial to take for the Septoria agricultural program?

Speaker #5: So accordingly, we still didn't initiate on the new target that we are focusing the field trial. We are now in the stage of validating our most promising molecules on attach on leaves.

Ofer Haviv: Currently, we still did not initiate on the new target that we are focusing the field trial. We are now in the stage of validating our most promising molecules on attached fungal leaves with the fungi, and the next step will be greenhouses. I am really excited from where we are today because the concentration of the small molecules that we are evaluating now, it is very, very low, which this is very, very important. We saw very strong response when it was tested on a fungi level. I really hope to start to see the indication also fungi on leaves, which this is the next step of our focus. This is the step when we are going to approach all the big chemical companies. The fact that we are focusing on Septoria, it is not a coincidence.

Speaker #5: With the only and the next step will be the greenhouses. I'm really excited about where we are today because the concentration of the small molecules that we are evaluating now is very, very low, which is very, very important.

Speaker #5: And we saw a very strong response when it was tested at the fungi level. And I really hope to start to see the indication also for fungi only, which is the next step of our focus.

Speaker #5: And this is the step when we are going to approach all the big chemical companies. And the fact that we are focusing on Septoria—it's not a coincidence.

Speaker #5: Septoria is one of the main, main fungi that all the big companies are looking for a solution for, because with what exists in the market, the fungi already develop a resistance.

Ofer Haviv: Septoria is one of the main fungi that all the big companies are looking for a solution for. Because what exists in the market, the fungi already developed a resistance, and everybody today is looking for a new mode of action. This is the program that we are focusing on. Of course, to find the chemistry that is working on this specific mode of action. I think this is what we have now in our hands. I am really looking to see what we can build commercially around this program when we start to present those results to the world lead chemical companies.

Speaker #5: And everybody today is looking for a new mode of action, which is the protein that we are focusing on. And of course, to find the chemistry that is working on this specific mode of action.

Speaker #5: And I think this is what we have now in our hands. So I'm really looking to see what we can build commercially around this program when we start to present those results to the world-lead chemical companies.

Speaker #4: The next question: When do you expect EVG R510 to enter the clinic?

Operator: The next question: When do you expect EVG510 to enter the clinic?

Speaker #5: So, I don't have the table in front of me, but in the near future, we are more focused on entering into the pre-clinical trial.

Ofer Haviv: I don't have in front of me the table, but in the near future, we are more focusing on entering into the preclinical trial. This is something that is closer, a milestone. I really hope that in some of our programs, at the H2 of next year, something that this would be reasonable to expect, at least in the first program that we initiate. I think that in my pitch, I shared that we are very, very excited to see that 2 from our 6 ongoing programs already moved from step 1 to step 2 in our workload scheme with a very, very promising result. It was better than what we expected, including our partners. We also are nicely advancing in our internal pipeline, which we already finished step 2, and now we are moving to step 3.

Speaker #5: This is something that is a closer milestone. And I really hope that in some of our programs in the second half of next year, this is something that would be reasonable to expect.

Speaker #5: At least in the first program that we initiate, I think that in my pitch I shared that we are very, very excited to see two out of our six ongoing programs already move from step one to step two in our workflow scheme.

Speaker #5: With a very, very promising result that was better than what we expected, and including our partners. And we also are nicely advancing in our internal pipeline, which we are finishing step two.

Speaker #5: And now we are moving to step three. Assuming we will end step three during next year, then we can start to talk about moving into the pre-clinical trial.

Ofer Haviv: Assuming we'll end step 3 during next year, then we can start to talk about moving into the preclinical trial. The minute that Evogene will move to the stage of preclinical trial company, I think this will be an inflection point that I hope and expect that it will also have effect on our company valuation and perception in the pharma industry.

Speaker #5: The minute that Evogene will move to the stage of a pre-clinical trial company, I think this will be an inflection point that I hope and expect will also have an effect on our company valuation and perception in the pharma industry.

Speaker #4: The next question: When does management plan to use an IR approach to bring investor outreach to new and existing shareholders? In my opinion, management has shot itself in the foot by pigeonholing itself to a single banker.

Operator: The next question: When does management plan to use an IR approach to bring investor outreach to new existing shareholders? In my opinion, management has shot itself in the foot by pigeonholing yourself to your single banker. I would like the C-suite and others to do NDR across US as IMO ChemPass AI is worth multiples of the market cap today. But due to ATMs and structural investors, our shares have been held hostage. Let's change our ways and bring the true value out.

Speaker #4: I would like the C-suite and others to do NDR across the US, as IMO Champ's AI is worth a multiple of the market cap today. But due to ATMs and structural investors, our shares have been held hostage.

Speaker #4: Let's change our ways and bring out the true value.

Ofer Haviv: Honestly, I definitely agree to almost everything that was said in this question. I think that we definitely need to explore Evogene to a much broader audience. I think that we need to meet with new investors and existing investors and to tell them the Evogene story. So why we haven't done it until now, if it's so clear, we are now in the position that if somebody would've told me a year ago that we will achieve all what we achieved already, I thought that maybe it's too good to be true. Because we started a new and this significant shift in our strategy a year and a half ago. A year and a half ago, what we can tell in the streets is also just the expectation, what we are planning to do, and what might happen.

Speaker #5: Honestly, I definitely agree with almost everything that was said in these questions. I think that we definitely need to explore Evogene to a much broader audience. I think that we need to meet with new investors and existing investors, and to tell the Evogene story.

Speaker #5: So, while we hadn't done it until now, if it's so clear, we are now in the position that if somebody had told me a year ago that we would achieve all that we have already, I would have thought maybe it's too good to be true.

Speaker #5: Because we started this significant shift in our strategy a year and a half ago. So a year and a half ago, what we can tell to the industry is it was just, you know, the expectation of what we were planning to do.

Speaker #5: And what might happen. A year and a half later, the reality is now that our expectation, our plans became the reality. And now I feel very, very comfortable to start to meet with investors and with family offices and with the institution financial institution and tell them not just the Evogene story but also to show them the result and the list of collaboration that we signed on and this list is going to increase and I think I feel that we have today now not just a story we have the reality that support our story and this is now the time to start to meet with investors in June, at the end of June, I participate in a conference in San Diego and we met with pharma companies, mid and small biotech companies, and it was the first time that when we tell the Evogene stories, es, all the results that we achieved, and when we show the numbers from the program that finished step one, and I see the reaction on the face of people when you show them the number of molecules that show positive results, this is where I felt that now we have what we need in order to make the difference when I'm meeting with investors.

Ofer Haviv: A year and a half later, the reality is now that our expectation, our plans became the reality. Now I feel very, very comfortable to start to meet with investors and with family offices and with financial institutions and tell them not just the Evogene story, but also to show them the results and the list of collaborations that we signed on and this list is going to increase. I feel that we have today now not just a story, we have the reality that supports our story. This is now the time to start to meet with the investors. in June, at the end of June, I participated in a conference in San Diego, and we met with pharma companies, mid and small biotech companies.

Ofer Haviv: It was the first time that when we tell the Evogene stories, all the results that we achieved, and when we show the numbers from the programs that finished step 1, I see the reaction on the face of people when you show them the number of molecules that show positive results. This is where I felt that now we have what we need in order to make the difference when I am meeting with investors. I am looking forward to finish the summer vacation and immediately, to work with more than one investment banker, to work with IR firms, and really to start to meet with potential investors and make sure that the audience of the work, whatever it is doing, will increase. When the results will come more and more frequently, I believe that it will also be reflected in our share price.

Speaker #5: And I'm looking forward to finishing the summer vacation and immediately working with more than one investment banker, to work with the IR firm, and really to start to meet with potential investors and make sure that the audience for the work Evogene is doing will increase. And when the results come more and more frequently, I believe that they will, it will also be reflected in our share price.

Speaker #5: So I have a strong belief that, yes, we need to be more out there, and we are now in the process of doing so.

Ofer Haviv: I have a strong belief that yes, we need to be more out there, and we are now in the process of ways to do so.

Speaker #4: The next question: How long does the heat-to-lead stage of development typically take?

Operator: The next question: how long does the hit-to-lead stage of development typically take?

Speaker #5: So the completion part, it shouldn't take too long. It's something around, like, two to three months. But before we are moving to step two, which—this is the 'Hit to Lead'—this is the name of the second step, we are, our partners or inside of Evogene, we order the predicted small molecules according to our computational analysis, and then we validate them in wet assays.

Ofer Haviv: The computational part, it shouldn't take too long. It's something around 2 to 3 months. Before we are moving to stage 2, which this is a hit-to-lead, this is the name of the second step. Our partners or inside of Evogene, we order the predicted small molecules according to our computational analysis, and then we validate them with assays. By doing so, we confirm the prediction, and we are using all of this information before we start the second computational round of analysis. What really takes more time is to order the small molecules, the time until they came to the lab, and the assay itself. This might take another few months. In total, it might take something between 4 to 5 months in order to see the results.

Speaker #5: And by doing so, we confirm the prediction, and we are using all of this information before we start the second round—the second competition round—of analysis.

Speaker #5: What really takes more time is to order the small molecules, the time until they get to the lab, and the assay itself.

Speaker #5: This might take another few months. So in total, it might take something between four to five months in order to see the results.

Speaker #5: When you're working with academic institutions, it might take longer because usually, academic institutions have the habit of doing everything a little bit slower than what you expect.

Ofer Haviv: When you're working with academic institutions, it might take longer because usually academic institutions, they have the habit to do everything a little bit slower than what you expect. When we are working with a commercial partner, things are moving much faster. When we are doing it by ourselves, this is when you see the fastest evolve in the program. This example, even though that we initiate our internal program, after we already worked, we engaged in two, maybe even three collaboration agreements. The program that is the most advanced, and now we initiate stage 3, is the internal program because we are moving much faster than academic institutions, some of our partners. To summarize the answer to the question, it's between 4 to 5 months. It could be shorter if we are doing it internally.

Speaker #5: When you're working with commercial partners, things are moving much faster. And when you're doing it by ourselves, so this is when you see the fastest evolving of—in the program.

Speaker #5: And in this example, even though we initiated our internal program after we had already engaged in two or maybe even three collaboration agreements, the program that is the most advanced—and for which we are now initiating stage three—is the internal program, because we are moving much faster than academic institutions or some of our partners.

Speaker #5: To summarize the answer to the question, it's between four to five months. It could be shorter if we are doing it internally. It might take longer if it's an academic institution, but this is the range.

Ofer Haviv: It might take longer if it's an academic institution, but this is the range.

Speaker #4: The next question: I'm a shareholder for a long time. Why has the price dropped so much until now? You have to do something to solve it.

Operator: The next question: I'm a shareholder for a long time. Why the price drops down so much till now? You have to do something to solve it.

Speaker #5: I'll take it. This is Neil. Thanks for the question. I'm also a shareholder, and I also share the frustration. We've done a very thorough strategic analysis of all of our assets already, a year and a half ago when I joined as Chairman.

Nir Nimrodi: I will take it. This is Nir. Thanks for the question. I am also a shareholder, and I also share the frustration. We have done a very thorough strategic analysis of all of our assets, already a year and a half ago when I joined as Chairman. I have spent personally a lot of time, and with my fellow board members and the management team, we have decided to focus very carefully but very intently on ChemPass. We feel that there is a differentiated asset that no one else has. Ofer was careful to say that, but I will say that after dozens of meetings with potential partners, it is a differentiated asset, and we believe that we will be able to evolve the six current collaborations into tangible products down the road that would be monetized.

Speaker #5: I've personally spent a lot of time, together with my fellow board members and the management team. We have decided to focus very carefully, but very intently, on CAMPASS.

Speaker #5: We feel that there is a differentiated asset that no one else has. Ofer was careful to say that, but I will say that after dozens of meetings with potential partners, it's a differentiated asset, and we believe that we will be able to evolve the six current collaborations into tangible products down the road that would be monetized. We believe that even before these products evolve into preclinical and clinical studies, we will cement additional collaborations, hopefully with larger companies—some of which are already spending significant amounts and resources on the use of AI for large molecules as well as small molecules.

Nir Nimrodi: We believe that even before these products evolve into preclinical and clinical studies, we will cement additional collaborations, hopefully with larger companies, some of which are already spending significant amounts and resources on the use of AI for large molecules as well as small molecules. We do believe that we have the data to show them to demonstrate the differentiated value of the product. Having said that, what would be the impact on the share price, if at all, and how soon, is not something I can comment on, nor I am willing to predict. But we believe the value will be there. It will be demonstrated very clearly. It will become tangible not only in our eyes, but also in the eyes of our partners, and a growing list of them. Eventually, that would result in an increase of the share price.

Speaker #5: And we do believe that we have the data to show them, to demonstrate the differentiated value of the product. With having said that, what would be the impact on the share price, if at all, and how soon, is not something I can comment on nor am I willing to predict, but we believe the value will be there.

Speaker #5: It will be demonstrated very clearly. It will become tangible not only in our eyes, but also in the eyes of our partners—and a growing list of them.

Speaker #5: And eventually, that would result in an increase in the share price. I also want to echo what Ofer said and repeat some of what I said.

Nir Nimrodi: I also want to echo what Ofer said and repeat some of what I have said. We are not just focusing on building value. We are also focusing on running a leaner, more agile, and more operationally focused organization. Again, the organization today is about one fourth in its size and even less so in terms of the burn. This is being done to preserve our runway and to be able to actually demonstrate this value. Again, all in all, we share the frustration, and we are acting very diligently to correct it.

Speaker #5: We're not just focusing on building value; we're also focusing on running a leaner, more agile, and more operationally focused organization. Again, the organization today is about one-fourth its previous size.

Speaker #5: And even less so in terms of the burn. This is being done to preserve our runway and to actually demonstrate this value.

Speaker #5: So again, all in all, we share the frustration, and we were acting very diligently to correct it.

Speaker #4: The next question: Is there any kind of plan to see if the Biomica candidates can be reduced to a single strain and still retain most activity?

Operator: The next question: is there any kind of plan to see if the Biomica candidates can be reduced to a single train and still retain most activity? The difference is huge in the regulatory world. I am talking about the difference between full drug path versus a dietary supplement.

Speaker #4: The difference is huge in the regulatory world. I am talking about the difference between the full drug path versus a dietary supplement.

Speaker #5: So first, it's important to emphasize that as part of our strategy to focus the company's activity on small molecule discovery, we reduced the level of Biomica activity significantly starting from 2025.

Ofer Haviv: First, it is important for me to emphasize that it is far from our strategy to focus the company activity on small molecule discovery. We reduced the level of Biomica activity significantly, starting from 2025. We were mainly focusing on BMC128, which this is our lead candidate for cancer. We finished phase I successfully in Q1 2026. We also have initial positive result that makes us very excited. Because we were short in budget, and because of our decision to focus on small molecules and not on microbe, we decided strategically to look for a partner that we can license those assets to.

Speaker #5: And we were mainly focusing on ABSC 128, which is our lead candidate for cancer. We finished Phase 1 successfully in the first quarter of 2026.

Speaker #5: And we also have initial positive results that make us very, very excited. But because we were short on budget, and because of our decision to focus on small molecules and not on microbes, we decided strategically to look for a partner that we can license those assets to.

Speaker #5: And we chose to work with a Chinese company that is focusing specifically on the area of drugs based on the human microbiome. This industry is nicely supported in China, which today is home to some of the leading companies in the biotech arena worldwide.

Ofer Haviv: We chose to work with a Chinese company that are focusing specifically on the area of drug based on human microbiome, which this industry is supported nicely at China, which today is one of the leading companies in the biotech arena worldwide. They are advancing the microbe forward. No doubt that if we will move from four microbes to one microbe, it will change significantly the regulation hurdle. The reason that we choose the four is because we felt that the total effect of all the four together is quite important because each one of the microbe is operated on a different mechanism, and altogether it serves the maximum effect that we were looking for. I think this is what also reflected in the result that we received.

Speaker #5: And they are advancing the microbes forward. No doubt that if we will move from four microbes to one microbe, it will change significantly the regulation hurdle but the reason that we choose this four is because we felt that the total effect of all the four together is quite important because each one of the microbes is operated on a different mechanism and all together it's a serve the maximum effect that we were looking for.

Speaker #5: And I think this is also reflected in the results that we received, and what was also very nice is that we saw the clinical indication supports the prediction of how those microbes are going to affect our body.

Ofer Haviv: What was also very nice is what we saw is that the clinical indication supports the prediction on how those microbes are going to affect our body. We are in direct contact with Lishan. Actually, today we had a board meeting of Biomica, that I am today leading this board meetings, and we talk with our colleagues in China, and they are now start validation of those consortium microbes. They also validate each one of them separately. Now they are the one that is leading the research and the commercial process of these microbes. Of course, if they will come to the conclusion that you can reduce the number of microbes, it is something that we would definitely be more than happy to do.

Speaker #5: So, we are in direct contact with Lishan. Actually, today we had a board meeting of Biomica, which I am currently leading, and during this board meeting we talked with our colleagues in China. They are now starting validation of those consortiums of microbes.

Speaker #5: They also validate each one of them separately, but now they are the ones that are leading the commercial, across the research and the commercial process of these microbes.

Speaker #5: Of course, if we'll come to the—if they will come to the conclusion that you can reduce the number of microbes, it's something that we would definitely be more than happy to do.

Speaker #5: Maybe the last thing I want to add is that when you're talking about building an IP position, having a combination of microbes puts you in a much stronger IP position rather than having only one microbe.

Ofer Haviv: Maybe the last thing I want to add is that when you are talking about building an IP position, when you have a combination of microbes, it puts you in a much stronger IP position rather than only one microbe. Maybe another reason to have a product based on two, three microbes is also from IP reason. I hope that I addressed this question. If not, I will be more than happy to do it offline.

Speaker #5: So maybe another reason to have a product based on two or three microbes is also from an IP reason. I hope that I addressed this question.

Speaker #5: If not, I will be more than happy to do it offline.

Speaker #4: The next question: Can you add the value for Evogene in the verb Biotics and Finally Foods? Those two items are really under-disclosed, compared to their relatively short term.

Operator: The next question, can you add the value for Evogene in Verb Biotics and Finally Foods? Those two items are really under disclosed compared to their relatively short-term.

Speaker #5: So, with respect to Finally Food, it's one of our subsidiaries. We hold in this company more than 30%. It's equity. I hope that this is correct.

Ofer Haviv: With respect to Finally Foods, it is one of our subsidiary. We hold in this company more than 30% in its equity. I hope that this is correct, because the company raised some money lately. The company is focusing on produce casein, which is a protein existing in milk, in potato. The whole concept was developed in Evogene and the researcher that was leading the program, they moved to, at the beginning, it was part of The Kitchen FoodTech Hub. They established a company, and the company name is Finally Foods. I am giving this information because I am not sure that everybody in the call knows about this activity. All of the wet lab, or maybe I should say, the majority of the wet lab, conducted by this company, was taking place in Evogene facility, in Evogene lab. Now, the majority of the greenhouse activity is taking place in Evogene Farm.

Speaker #5: Because the company raised some money lately, the company is focusing on producing casein, which is a protein existing in milk. In potato. The whole concept was developed in Evogene.

Speaker #5: And the researcher that was leading the program they moved to, at the beginning, it was part of the Kitchen Hub. They established a company, and the company name is Finally Food.

Speaker #5: I'm giving this information because I'm not sure that everybody on the call knows about this activity. All of the wet lab—or maybe I should say the majority of the wet lab—conducted by this company was taking place in the Evogene facility, in the Evogene lab.

Speaker #5: And now the majority of the greenhouse activity is taking place in Evogene farm, and the company has very nice and promising results. We are very excited about it.

Ofer Haviv: The company has very nice and promising results, and we are very excited about it. Due to our decision to focus on small molecules, we are not planning to invest directly in this company. I am a board member in this company. We are the major shareholder. Of course, if we will come to the conclusion that from financial perspective, it makes sense to keep our holding in the company. In future round, we will consider to participate. At least for now, it is not part from our core strategy. You can imagine that I am more than excited and pleased to see the progress of this company, moving forward with the idea of producing casein protein, and other proteins that usually exist in milk, in potato. They had a very nice result based on the last update I received from them.

Speaker #5: Due to our decision to focus on small molecules, we are not planning to invest directly in this company. I'm a board member in this company.

Speaker #5: We are the major shareholder. But of course if we'll come to the conclusion that from financial perspective it makes sense to keep our holding in this company.

Speaker #5: So, in future rounds, we will consider participating. But at least for now, it's not part of our core strategy. But you can imagine that I'm more than excited and pleased to see the progress of this company moving forward with the idea of producing casein protein and other proteins that usually exist in milk.

Speaker #5: In potato, and they have very nice results based on the last update I received from them.

Speaker #4: The next question: The APH1 and the APTH1, is the program dead or is it possible to license it to someone like Adama or Syngenta?

Operator: The next question, the APH1 and the APTH1, is this program dead or is it possible to license it to someone like ADAMA or Syngenta?

Ofer Haviv: ADAMA or Syngenta. APTH1 is a protein that we were focusing on for herbicides. We had the collaboration in this field with Bayer. We announced that we stopped this collaboration at H1 of this year. There is good news and bad news related to this announcement. I will start with the bad news. The bad news was that what it turns out is that the protein itself, even when you stop its activity, and the idea was to develop an herbicide weed killer. It turns out that when you stop the protein activity, the weed at the beginning show that they are getting weak and it looks like they are going to die. But after a while, they somehow recover and the understanding is that this specific protein is not essential enough in order to kill the weed.

Speaker #5: Adama or Syngenta. So, APTH1 is a protein that we were focusing on for herbicides. We stopped, and we have a collaboration in this field with Bayer.

Speaker #5: And we announced that we stopped this collaboration in the first half of this year. There is good news and bad news related to this announcement.

Speaker #5: I will start with the bad news. The bad news was that what it turned out is that the protein itself, even when you stop its activity—so, at the end, the idea was to develop a herbicide, a weed killer.

Speaker #5: Okay. So it turned out that when you stop the protein activity, the weed at the beginning shows that they are getting weak, and it looks like they are going to die.

Speaker #5: But after a while, they somehow recover. And the understanding is that this specific protein is not essentially enough in order to kill the weed.

Speaker #5: And this is something that our partners saw only at a much more advanced stage, and the perception was that the molecule we discovered was doing the job; they were doing what we were expecting from them.

Ofer Haviv: This is something that our partners saw only in very advanced stage. The perception was that the molecule that we discovered, they were doing what we were expecting from them. They stopped the protein activity. This was the main expectation from Evogene, to find the molecules that are going to stop the protein activity. The problem wasn't the molecule, the problem was the protein itself. The protein that we were supposed to stop its activity, was not essential enough to the existing of the weed. This is why both Bayer and Evogene decided to stop focusing on this target. I am not sure that we will succeed to generate enough interest with other partners with respect to this specific protein.

Speaker #5: They stopped the protein activity. This was the main expectation from Evogene—to find the molecules that are going to stop the protein activity. The problem wasn't the molecule.

Speaker #5: The problem was that the protein itself, the protein that we were supposed to stop its activity, was not essential enough to the existence of the weed.

Speaker #5: And this is why both Bayer and Evogene decided to stop focusing on this target. So I'm not sure that we will succeed in generating enough interest with other partners with respect to this specific protein.

Speaker #5: The good news that came from this work is that I think Bayer felt very positive and pleased with the Evogene work in this project, because as I said, our target was to find the right small molecules that are going to bind to this protein and stop its activity, and we succeeded in doing so.

Ofer Haviv: The good news came from this work is that I think that Bayer felt very positive and pleased from the Evogene work in this project because as I said, our target was to find the right small molecules that are going to bind to this protein and stop its activity, and we succeed in doing so. This is when both party exposed that the protein is not essential enough to kill the weed. My belief and expectation is that this positive impression on Evogene technology, I hope that it will lead to a new discussion with Bayer on new program, new project, and I believe that there is more to come in respect of the relationship between the two companies.

Speaker #5: And this is when and how we both partly exposed that the protein is not essentially enough to kill the weed. So my belief and expectation is that this positive impression on Evogene technology—I hope that it will lead to new discussions with Bayer or new programs, new projects—and I believe that there is more to come in respect of the relationship between these two companies.

Speaker #5: I can't disclose much, but I really hope that the good impression and the great atmosphere between the two teams will be translated into expanding and continuing the commercial relationship between the two parties.

Ofer Haviv: Again, this was much, but I really hope that the good impression, the great atmosphere between the two teams will be translated into expanding and continuation of the commercial relationship between the two parties.

Operator: There are no further questions at this time. Mr. Haviv, would you like to make a concluding statement?

Speaker #4: There are no further questions at this time. Mr. Haviv, would you like to make a concluding statement?

Speaker #5: Yes. I would like to thank everybody that participated in this analyst call. We highly appreciate your time. I think the company is in a really great position to progress and prosper.

Ofer Haviv: Yes. I would like to thank everybody that participated in this analyst call. We highly appreciate the time. I think the company is in a really great position to progress and prosper. We are in the right space. Small molecules in pharma, it is huge stake. I believe it is exactly the same in the ag industry. I am looking forward to continue to update you in future analyst calls on additional achievements. If you have any additional questions that maybe I did not succeed to address in this call, do not hesitate, call me. I will be available to any additional questions. I will be also very happy if needed to meet face to face, to elaborate more about the company. Thank you very much, and enjoy the rest of the week.

Speaker #5: We are in the right space—more molecules in pharma. It's a huge, huge space. I believe it's exactly the same in the ag industry.

Speaker #5: And I'm looking forward to continuing to update you in future analyst calls on additional achievements. And if you have any additional questions that maybe I didn't succeed in addressing in this call, don't hesitate.

Speaker #5: Call me. I will be available for any additional questions. And I will also be very happy, if needed, to meet face to face to elaborate more about the company.

Speaker #5: Thank you very much, and enjoy the rest of the week.

Operator: Thank you. This concludes Evogene's Q2 2026 results conference call. Thank you for your participation. You may go ahead and disconnect.